OMER

Omeros Corporation

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$153.5M

Burn Rate (Qtr)

-$38.5M

Company Profile

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

OMIDRIA (phenylephrine and ketorolac intraocular solution)

Cataract surgery or intraocular lens replacement

Quarterly Sales (Approved)

March 05, 2021 (Est)

Narsoplimab (MASP-2 inhibitor, lectin pathway)

Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

BLA Acceptance

January 31, 2020 (Est)

Narsoplimab (MASP-2 inhibitor, lectin pathway)

IgA Nephropathy (IgAN)

Phase 3 Data

TBD

Narsoplimab (MASP-2 inhibitor, lectin pathway)

Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3 Data

TBD

OMS405: Small-molecule peroxisome proliferator-activated receptor gamma (PPARγ) agonist

Opioid and Nicotine Addiction

Phase 2 Data

TBD

Narsoplimab (MASP-2 inhibitor, lectin pathway)

Lupus Nephritis & Other Renal Diseases

Phase 2 Data

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon